Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Dental Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schütz, T.C.B.
Right arrow Articles by Tufik, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schütz, T.C.B.
Right arrow Articles by Tufik, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Joint Disorders
*Sleep Disorders
*Temporomandibular Joint Dysfunction
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Effects of COX-2 Inhibitor in Temporomandibular Joint Acute Inflammation

T.C.B. Schütz*, M.L. Andersen and S. Tufik

Department of Psychobiology–Universidade Federal de São Paulo, Escola Paulista de Medicina (UNIFESP/EPM), Rua Napoleão de Barros, 925, Vila Clementino-SP-04024-002, São Paulo, SP, Brazil


Figure 1
View larger version (28K):
[in this window]
[in a new window]

 
Figure 1. (A) Effect of cyclo-oxygenase-2 inhibitor on sleep efficiency in the acute inflammatory model induced by Freund’s adjuvant application to the TMJ on 2 light periods of recording. Each set of columns represents an experimental group. (B) Effect of cyclo-oxygenase-2 inhibitor on sleep parameters in the acute inflammatory model induced by Freund’s adjuvant application in the TMJ on 2 light periods of recording. SHAM group: injected with saline. FA group: injected with Freund’s adjuvant. Saline (SHAM/COX2i) and Freund’s adjuvant (FA/COX2i) injected into the TMJ treated with etoricoxib (COX-2i, 90 mg/kg, p.o.). W1, wake day 1; W2, wake day 2; nREM1, non-REM sleep day 1; nREM2, non-REM sleep day 2; REM1, rapid eye movement sleep day 1; REM2, rapid eye movement sleep day 2. The values are expressed as mean ± SD. *Differ from SHAM group (p < 0.05). #Differ from Freund’s adjuvant group (p < 0.01). ¥Differ from SHAM/COX2i group (p < 0.05). {euro}Differ from first day of SHAM/COX2i group (p < 0.01). N = 8/group.

 

Figure 2
View larger version (11K):
[in this window]
[in a new window]

 
Figure 2. Effect of cyclo-oxygenase-2 inhibitor on sleep latency (A) and REM sleep latency (B) in the acute inflammatory model induced by Freund’s adjuvant application in the TMJ on 2 light periods of recording. SHAM group: injected with saline. FA group: injected with Freund’s adjuvant. Saline (SHAM/COX2i) and Freund’s adjuvant (FA/COX2i) injected into the TMJ treated with etoricoxib (COX-2i, 90 mg/kg, p.o.). The values are expressed as mean ± SD. *Differ from the SHAM group (p < 0.001). {euro}Differ from first day of SHAM/COX2i group (p < 0.01). {dagger}Differ from first day of the FA/COX2i group (p < 0.05). N = 8/group.

 

Figure 3
View larger version (9K):
[in this window]
[in a new window]

 
Figure 3. Effect of cyclo-oxygenase-2 inhibitor on arousals in the acute inflammatory model induced by Freund’s adjuvant application in the TMJ on 2 light periods of recording. SHAM group: injected with saline. FA group: injected with Freund’s adjuvant. Saline (SHAM/COX2i) and Freund’s adjuvant (FA/COX2i) injected into the TMJ treated with etoricoxib (COX-2i, 90 mg/kg, p.o.). The values are expressed as mean ± SD. *Differ from SHAM group (p < 0.05). #Differ from Freund’s adjuvant group (p < 0.05). N = 8/group.

 

Figure 4
View larger version (36K):
[in this window]
[in a new window]

 
Figure 4. Representative 12-hour light period hypnogram on the first day for a SHAM (A), Freund’s adjuvant (FA) (B), SHAM/COX2i (C), and FA/COX2i (D) rats. Values were recorded at 30-second intervals in each stage. ’W’ represents a period of wakefulness; nREM, non-REM sleep; and REM, REM sleep. Note the marked fragmentation and reduced long sleep period in orofacial pain, and marked alterations after the treatment with etoricoxib.

 

Journal of Dental Research, Vol. 86, No. 5, 475-479 (2007)
DOI: 10.1177/154405910708600516


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?